PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · IEX Real-Time Price · USD
32.63
-0.18 (-0.55%)
At close: Jul 19, 2024, 4:00 PM
32.75
+0.12 (0.37%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $927.56M in the twelve months ending March 31, 2024, with 20.39% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $210.12M. In the year 2023, PTC Therapeutics had annual revenue of $937.82M with 34.20% growth.
Revenue (ttm)
$927.56M
Revenue Growth
+20.39%
P/S Ratio
2.70
Revenue / Employee
$932,219
Employees
995
Market Cap
2.50B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
Dec 31, 2011 | 105.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Integra LifeSciences Holdings | 1.53B |
Astrana Health | 1.45B |
Progyny | 1.11B |
UFP Technologies | 407.33M |
Certara | 360.69M |
Vericel | 207.78M |
Kymera Therapeutics | 79.41M |
Intellia Therapeutics | 52.60M |
PTCT News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT - GlobeNewsWire
- 3 days ago - PTCT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today! - Accesswire
- 4 days ago - PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today! - Accesswire
- 5 days ago - PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today! - Accesswire
- 6 days ago - PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - GlobeNewsWire
- 6 days ago - PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Shareholders to Contact the Firm Today! - Accesswire
- 7 days ago - PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds PTC Therapeutics, Inc Shareholders to Lead Class Action Lawsuit! - Accesswire
- 9 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT - GlobeNewsWire